December 3, 2025 4:30 PM EST to December 3, 2025 5:30 PM EST
NRx Pharmaceuticals, Inc. Chairman, and Chief Executive Officer, Jonathan Javitt, M.D., M.P.H will present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.- on Wednesday, December 3rd at 4:30 PM EST.
The presentation will provide an update on the Company’s expanded focus following progress achieved over the past year across investigational drugs, medical devices, and interventional psychiatric therapies for suicidal depression, PTSD, and related conditions. As previously announced, the Company has begun generating clinical revenue and has made meaningful progress in drug development since its appearance at NobleCon 2024.
Interested investors and guests of the Company are welcome to attend at a discounted rate. Please register here using the discount code NRXPNOBLECON.
A high-definition video webcast of the presentation will be available the following day on the Company's website https://ir.nrxpharma.com/events, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek www.channelchek.com, the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event.
Jonathan Javitt, M.D., M.P.H., Founder, Chairman, and Chief Executive Officer of NRx Pharmaceuticals will provide a corporate update, including a discussion of the Company’s plan to launch a low-dose D-Cycloserine (DCS) product based on recent medical evidence that low-dose DCS more than doubles the clinical effectiveness of Transcranial Magnetic Stimulation (TMS) in treating depression. The presentation will provide additional detail on the Company’s newly-acquired clinical operations in Florida and their active participation with the US Department of Veterans Affairs to treat veterans with suicidal depression and PTSD. Dr. Javitt will share the Company’s recent participation in the Stop Suisilence summit and his keynote presentation on neuroplastic treatments for suicidal depression at the US Army Museum at Fort Belvoir, VA, attended by members of Congress, senior leaders of the US Department of Veterans Affairs, and flag rank officers of the US Department of Defense.
A live webcast of the presentation will be available to registered attendees of the conference. Following the event, a replay of the presentation will be accessible under the “Events” section of the Company’s website at https://ir.nrxpharma.com/events.
Management will also be participating in one-on-one investor meetings throughout the conference. Investors wishing to meet 1x1 with company management can reach out to Giorgia Pigato, from Noble Capital Markets, at gpigato@noblecapitalmarkets.com.
Jonathan Javitt, M.D., M.P.H., Chief Executive Officer of NRx Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 at 4:30PM EST.
Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the NRx Pharmaceutical management team should contact their H.C. Wainwright representative.
Dr. Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE, will deliver a corporate presentation highlighting the company's latest advances. The presentation will be available on demand to registered attendees beginning at 7:00 a.m. Eastern Time on Monday, June 16, 2025. In addition, the company will be participating in one-on-one meetings with investors throughout the conference.
Due to a personnel change at HC Wainright, the NRX Pharmaceuticals Fireside Discussion planned for tomorrow, April 22, 2025, will be rescheduled shortly.
Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals presented a Company update at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which took place on Wednesday, February 12th, 2025. Watch the webcast here.
January 13, 2025 9:00 AM PST to January 16, 2025 4:00 PM PST
NRx Pharmaceuticals will be participating in 1x1 meetings in San Francisco during the Annual J.P. Morgan Healthcare Conference on January 13-16, 2025, in San Francisco, CA.
For further information and to schedule meetings, please contact: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals Co-Chief Executive Officer, HOPE Therapeutics, Inc. mduffy@nrxpharma.com
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco
HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) subsidiary, is inviting Qualified Institutional Investors to an investor workshop to support planned acquisitions for a national network of interventional psychiatry practices focused on treatment suicidal depression and PTSD.
For further information, contact: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals Co-Chief Executive Officer, HOPE Therapeutics, Inc. mduffy@nrxpharma.com
Corporate Presentation
Click here to view our corporate presentation or on the image below
